

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 11-12

exact bonds :

2-7

isolated ring systems :

containing 1 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 11:CLASS 12:CLASS
13:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:52:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 160 TO ITERATE

100.0% PROCESSED 160 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2442 TO 3958

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 10:52:25 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3490 TO ITERATE

100.0% PROCESSED 3490 ITERATIONS

31 ANSWERS

SEARCH TIME: 00.00.01

L3 31 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'CAPLUS' ENTERED AT 10:52:29 ON 27 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Mar 2007 VOL 146 ISS 14
FILE LAST UPDATED: 26 Mar 2007 (20070326/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 18 L3

=> d ibib abs hitstr tot


L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2005.688727 CAPLUS
 DOCUMENT NUMBER: 143127885
 TITLE: Pharmacological attenuation of apoptosis in reoxygenated endothelial cells
 AUTHOR(S): Kabakov, A. E.; Budagova, K. R.; Malyutina, Y. V.; Latchman, D. S.; Caermely, P.
 CORPORATE SOURCE: Medical Radiology Research Center, Obninsk, 249016, Russia
 SOURCE: Cellular and Molecular Life Sciences (2004), 61(24), 3076-3086
 CODEN: CMLSPI; ISSN: 1420-682X
 PUBLISHER: Birkhaeuser Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB BRX-235 (Iroxanadine), a novel drug developed by Biorex (Hungary), was previously characterized as a vasculoprotector against atherosclerosis, an activator of p38 kinase, and an enhancer of stress-responsive heat shock protein (Hsp) expression. The present data demonstrate that BRX-235 may improve survival of vascular endothelial cells (ECs) following ischemia/reperfusion stress. ECs cultured from human umbilical veins were exposed to hypoxia/reoxygenation to mimic ischemia/reperfusion. Caspase activation and apoptosis were monitored in the reoxygenated cells. Addition of BRX-235 (0.1 - 1 µM) to culture medium prior to hypoxia or at start of reoxygenation significantly reduced the caspase-dependent apoptosis. The cytoprotection conferred by the pre-hypoxic drug administration was sensitive to quercetin and seems to be based on enhanced Hsp accumulation in stressed ECs. In the case of post-hypoxic drug administration, the cytoprotection was strongly inhibited by SB202190 and SB203580 and appears to be associated with enhanced p38 kinase activation in reoxygenated ECs.
 IT 276690-58-5, Iroxanadine
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (BRX-235; pharmacol. attenuation of apoptosis in reoxygenated endothelial cells)
 RN 276690-58-5 CAPLUS
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-, (-)- (9CI) (CA INDEX NAME)
 Rotation (-).

own work

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2003.551488 CAPLUS
 DOCUMENT NUMBER: 139:117340
 TITLE: Carboxamide derivatives and their use in the treatment of vascular diseases
 INVENTOR(S): Jegen Csakai, Zita; Marvanyon, Ede; Ueroegdi, Laszlo; Batho Torok, Magdolna; Denes, Laszlo
 PATENT ASSIGNEE(S): Biorex Kutato es Fejlesztok Rt., Hung.
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIIXXD
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057664	A1	20030717	WO 2003-HU3	20030110
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, QA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2471752	A1	20030717	CA 2003-2471752	20030110
AU 2003022104	A1	20030724	AU 2003-202104	20030110
BR 2003006778	A	20041228	BR 2003-4778	20030110
EP 1492763	A1	20050105	EP 2003-700962	20030110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, PI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
HU 200402526	A2	20050329	HU 2004-2526	20030110
CN 1615296	A	20050511	CN 2003-802151	20030110
JP 2005514418	T	20050519	JP 2003-557981	20030110
NZ 533795	A	20060331	NZ 2003-533795	20030110
US 2005043395	A1	20050224	US 2004-889966	20040712
NO 2004003029	A	20041011	NO 2004-3029	20040713
US 2006058294	A1	20060316	US 2005-501029	20050725
PRIORITY APPLN. INFO.:			HU 2002-109	A 20020111
			HU 2002-4362	A 20021217
			WO 2003-HU3	W 20030110

GI




AB Carboxamides (structures not given) were prepared for use in the
 Habte

L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 of vascular diseases. Thus, the piperidine N-oxide (I) was obtained by oxidizing the piperidine with 3-ClC6H4CO2OH. At 5 mg/kg in isolated rat aorta I caused 82.5% reversal of vasoconstriction induced by 1X10-5 M acetylcholine.
 IT 561306-37-4P 561306-38-5P 561306-40-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of carboxamide deriva. and their use in the treatment of vascular diseases)
 RN 561306-37-4 CAPLUS
 CN 2-Piperidinone, 1-[[5,6-dihydro-3-(3-pyridinyl)-2H-1,2,4-oxadiazin-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 561306-38-5 CAPLUS
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-3-(1-oxido-3-pyridinyl)-5-(1-piperidinylmethyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 561306-40-9 CAPLUS
 CN 4-Piperidinol, 1-[[5,6-dihydro-3-(3-pyridinyl)-2H-1,2,4-oxadiazin-5-yl]methyl]- (9CI) (CA INDEX NAME)




03/27/2007

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 IT 276690-58-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of carboxamide deriva. and their use in the treatment
 of
 vascular diseases)
 RN 276690-58-5 CAPLUS
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-[(1-piperidinylmethyl)-3-(3-pyridinyl)-,
 (-)- (9CI) (CA INDEX NAME)
 Rotation (-).




IT 561306-35-2P 561306-36-3P 561306-39-6P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 (preparation of carboxamide deriva. and their use in the treatment
 of
 vascular diseases)
 RN 561306-35-2 CAPLUS
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-3-[(1-oxido-3-pyridinyl)-5-(1-
 piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 561306-36-3 CAPLUS
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-[[4-(phenylmethyl)-1-
 piperidinylmethyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 561306-39-6 CAPLUS
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-[(1-oxido-1-piperidinylmethyl)-3-(1-
 oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:551954 CAPLUS
 DOCUMENT NUMBER: 138:49687
 TITLE: Pharmacologically activated migration of aortic
 endothelial cells is mediated through p38 SAPK
 Denes, Laszlo; Jednakovits, Andras; Hargitai, Judit;
 Penzes, Zoltan; Balla, Andras; Talosi, Laszlo;
 Krajcsi, Peter; Cserehely, Peter
 CORPORATE SOURCE: Biorex Research and Development Company, Veszprem,
 H-8201, Hung.
 SOURCE: British Journal of Pharmacology (2002), 136(4),
 597-603
 CODEN: BJPCBM; ISSN: 0007-1188
 PUBLISHER: Nature Publishing Group
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Impairment in endothelial cell (EC) function plays a central role in
 vascular diseases (e.g. atherosclerosis, restenosis, diabetic
 angiopathies, microvascular angina, peripheral arterial disease).
 BRX-235
 [a novel small mol. synthesized by Biorex, Hungary] has a potent vascular
 protective activity in different in vivo and in vitro studies. Since the
 importance of the p38 pathway in EC homeostasis and migration in
 particular is well documented, we have carried out studies to address the
 role of the p38 stress activated protein kinase (p38 SAPK) in the mode of
 action of BRX-235. In this study, Bovine aortic endothelial cells were
 used in a wounding migration assay (WMA) and for Western-blot anal. to
 study the effect and mol. mechanism of BRX-235-induced EC migration. The
 bovine aortic endothelial (BAE) cells were shown to be good models for EC
 migration. Both endothelial cell growth factor (ECGF) and
 BRX-235-induced BAE cell migration were shown to be inhibited by SB
 203580, a specific inhibitor of p38 SAPK. It was also shown that,
 BRX-235
 induces phosphorylation of p38 SAPK without affecting p38 SAPK protein
 levels. Thus, BRX-235 acts upstream of p38 SAPK. In summary, we have
 shown that p38 SAPK is a potential pharmacol. mediator for candidate
 drugs

that target the endothelium.
 IT 203805-20-3, BRX 235
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (pharmacol. activated migration of aortic endothelial cells is
 mediated
 through p38 SAPK)
 RN 203805-20-3 CAPLUS
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-[(1-piperidinylmethyl)-3-(3-pyridinyl)-
 (9CI) (CA INDEX NAME)



Habte

L4 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

03/27/2007


L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:664173 CAPLUS
 DOCUMENT NUMBER: 133:35901
 TITLE: Cardiovascular effects of BRX-005: comparison to bimolomol
 AUTHOR(S): Kortvely, Agnes; Sziget, Gyula; Geisztlyi, Rudolf; Zeuge, Judit; Banyasz, Tamas; Magyar, Janos; Szilgiet, Peter; Kovacs, Laszlo; Jednakovits, Andras; Szentmiklosi, A. Jozsef; Nanas, Peter P.
 CORPORATE SOURCE: Department of Physiology, University Medical School of Debrecen, Debrecen, H-4012, Hung.
 SOURCE: Life Sciences (2000), 67(14), 1783-1789
 CODEN: LIFSAR; ISSN: 0024-3205
 PUBLISHER: Elsevier Science Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Concentration-dependent effects of BRX-005, the novel heat shock protein coinducer, cardioprotective and vasoprotective agent, on intracellular calcium transients and contractility were studied in Langendorff-perfused guinea pig hearts loaded with the fluorescent calcium indicator dye Fura-2. BRX-005 increased peak left ventricular pressure, the rate of force development and relaxation significantly in a concentration-dependent manner. The amplitude of $[Ca^{2+}]_i$ transients was left unaltered by the drug. In contrast to BRX-005, bimolomol increased both contractility and the amplitude of $[Ca^{2+}]_i$ transients. In canine ventricular cardiomyocytes high concns. of BRX-005 had no effect on depolarization, whereas bimolomol suppressed action potential upstroke markedly. In guinea pig pulmonary artery preps. precontracted with phenylephrine, BRX-005 induced concentration-dependent relaxation. This effect of BRX-005 was independent of the integrity of endothelium indicating that vasorelaxant effect of the drug develops directly on vascular smooth muscle.
 IT 203805-20-3, BRX 005
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
 USES (Uses)
 (cardiovascular effects of BRX-005 vs. bimolomol)
 RN 203805-20-3 CAPLUS
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2000:421137 CAPLUS
 DOCUMENT NUMBER: 133:63958
 TITLE: Optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
 INVENTOR(S): Jednakovits, Andras; Urogsi, Laszlo; Denes, Laszlo; Kurucz, Istvan; Marvanyos, Ede; Barabas, Mihaly; Bacsy, Erno; Korom, Zeuzsanna; Nagy, Zoltan; Urge, Laszlo; Szilbereky, Jeno; Acsai, Karoly; Krajcsi, Peter; Csakai, Zita; Torok, Magdolna
 PATENT ASSIGNEE(S): Biorex Kutato Es Fejlesztő Rt., Hung.; et al.
 SOURCE: PCR Int. Appl., 18 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035914	A1	20000622	WO 1999-HU95	19991207
W: AU, BG, BR, CA, CZ, EE, HR, IL, JP, KR, LT, LV, NO, PL, RO, RU, SI, SK, UA, US, YU, ZA				
RM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
HU 9802897	A2	20001128	HU 1998-2897	19981214
HU 9802897	A3	20010828		
CA 2340734	A1	20000622	CA 1999-2340734	19991207
BR 9913982	A	20010612	BR 1999-13982	19991207
EP 1147105	A1	20011024	EP 1999-961225	19991207
EP 1147105	B1	20040506		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EE 200100188	A	20020815	EE 2001-188	19991207
EE 4551	B1	20051017		
JP 2002532498	T	20021002	JP 2000-588174	19991207
AU 765336	B2	20030918	AU 2000-17906	19991207
RU 2229538	C2	20040127	RU 2001-118854	19991207
AT 266027	T	20040515	AT 1999-961225	19991207
PT 1147105	T	20040730	PT 1999-961225	19991207
ES 2219091	T3	20041116	ES 1999-961225	19991207
IL 141515	A	20050925	IL 1999-141515	19991207
ZA 2001001182	A	20020212	ZA 2001-1182	20010212
HR 2001000133	A1	20020228	HR 2001-133	20010223
HR 2001000133	B1	20050228		
BG 105342	A	20011231	BG 2001-105342	20010314
NO 2001002310	A	20010510	NO 2001-2310	20010510
NO 317649	B1	20041129		
US 6384029	B1	20020507	US 2001-762949	20010515
PRIORITY APPLN. INFO.:			HU 1998-2897	A 19981214
			WO 1999-HU95	W 19991207

AB The invention relates to (-)-5,6-dihydro-5-((1-piperidinylmethyl)-3-(3-pyridyl))-4H-1,2,4-oxadiazine (I) preparation and use in pharmaceuticals for the treatment of heart and vascular diseases. I was prepared by resolution of the racemic compound, salts of I prepared and pharmaceutical formulations containing I
 habte


L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE


L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 203805-20-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use
 in treatment of vascular diseases)
 RN 203805-20-3 CAPLUS
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)



IT 276690-58-5P 276690-59-6P 276690-60-9P
 276690-61-0P 276690-62-1P 276690-63-2P
 276690-64-3P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (optically active pyridyl-4H-1,2,4-oxadiazine derivative and its use
 in treatment of vascular diseases)
 RN 276690-58-5 CAPLUS
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




RN 276690-59-6 CAPLUS
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-, monohydrochloride, (-)- (9CI) (CA INDEX NAME)

Rotation (-).

03/27/2007

L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HCl

RN 276690-60-9 CAPLUS
 CN 2H-1,2,4-Oxadiazine,
 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-,
 (-)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 276690-58-5
 CMP C14 H20 N4 O


Rotation (-).




CM 2

CRN 110-16-7
 CMP C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● HBr

RN 276690-63-2 CAPLUS
 CN 2H-1,2,4-Oxadiazine,
 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-,
 (-)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 276690-58-5
 CMP C14 H20 N4 O


Rotation (-).



CM 2

CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.



RN 276690-64-3 CAPLUS
 CN 2H-1,2,4-Oxadiazine,
 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-,
 (-)-, monomethanesulfonate (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 276690-61-0 CAPLUS
 CN 2H-1,2,4-Oxadiazine,
 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-,
 (-)-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 276690-58-5
 CMP C14 H20 N4 O

Rotation (-).



CM 2

CRN 7664-93-9
 CMP H2 O4 S



RN 276690-62-1 CAPLUS
 CN 2H-1,2,4-Oxadiazine,
 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-,
 monohydrobromide, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 1

CRN 276690-58-5
 CMP C14 H20 N4 O

Rotation (-).



CM 2

CRN 75-75-2
 CMP C H4 O3 S



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1998:134011 CAPLUS
 DOCUMENT NUMBER: 128:208909
 TITLE: Pharmaceutical products for curing and preventing illnesses connected with the malfunction of vascular endothelial cells
 INVENTOR(S): Jednakovits, Andrea; Urogi, Laszlo; Marvanyos, Ede; Barabas, Mihaly; Kurucz, Istvan; Bacsy, Erno; Koranyi, Laszlo; Erdo, Sendor; Dorman, Gyorgy; Vitai, Marta; Schmidt, Gyorgy; Sinka, Marta; et al.
 PATENT ASSIGNEE(S): Biorex Kutato Es Fejleszto Rt., Hung.
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9806400	A2	19980219	WO 1997-HU44	19970806
WO 9806400	A3	19980326		
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, IL, IS, JP, KR, LR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZM, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
HU 9701349	A1	20000528	HU 1997-1349	19970804
CA 2262997	A1	19980219	CA 1997-2262997	19970806
AU 9737049	A	19980306	AU 1997-37049	19970806
AU 739614	B2	20011018		
EE 990044	A	19990816	EE 1999-44	19970806
EE 4044	B1	20030616		
EP 966283	A2	19991229	EP 1997-933813	19970806
EP 966283	B1	20060614		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001504446	T	20010403	JP 1998-509527	19970806
RU 2195273	C2	20011227	RU 1999-104609	19970806
IL 128256	C	20040512	IL 1997-128256	19970806
SK 284301	B6	20050103	SK 1999-154	19970806
PL 190673	B1	20051230	PL 1997-331601	19970806
AT 329592	T	20060715	AT 1997-933813	19970806
PT 966283	T	20060831	PT 1997-933813	19970806
ZA 9707043	A	19980921	ZA 1997-7043	19970807
NO 9900547	A	19990325	NO 1999-547	19990205
BG 64456	B1	20050331	BG 1999-103194	19990222
US 6143741	A	20001107	US 1999-230941	19991206
HK 1025506	A1	20070105	HK 2000-103903	20000628
PRIORITY APPLN. INFO.:			HU 1996-2204	A 19960809
			HU 1997-1349	A 19970804

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:436213 CAPLUS
 DOCUMENT NUMBER: 127:55919
 TITLE: Hydroxylamine derivatives useful for enhancing molecular chaperon production and the preparation thereof
 INVENTOR(S): Vigh, Laszlo; Literati Nagy, Peter; Szilbereky, Jeno; Urogi, Laszlo; Jednakovits, Andrea; Jaszlits, Laszlo; Biro, Katalin; Marvanyos, Ede; Barabas, Mihaly; Hegedues, Erzsébet; Koranyi, Laszlo; Kuerthy, Maria; Balogh, Gabor; Horvath, Ibolya; Torok, Zolt; Udvardy, Ede; Dorman, Gyorgy; Medzihradsky, Denes; Mezes, Bea; Kovacs, Eszter; Duda, Erno; Parkas, Beatrix; Glatz, Attila; et al.
 PATENT ASSIGNEE(S): Hung.
 SOURCE: PCT Int. Appl., 179 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9716439	A1	19970509	WO 1996-HU64	19961101
W: AU, BG, BR, CA, CN, CZ, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
HU 76659	A2	19971028	HU 1995-3141	19951102
HU 222994	B1	20040128		
HR 960508	B1	20041031	HR 1996-508	19961031
CA 2209167	A1	19970509	CA 1996-2209167	19961101
AU 9673263	A	19970522	AU 1996-73263	19961101
AU 720195	B2	20000525		
EP 801649	A2	19971022	EP 1996-935195	19961101
EP 801649	B1	20020807		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1177351	A	19980325	CN 1996-192305	19961101
BR 9607565	A	19990720	BR 1996-7565	19961101
IL 121126	A	20020725	IL 1996-121126	19961101
AT 221880	T	20020815	AT 1996-935195	19961101
ES 2176502	T3	20021201	ES 1996-935195	19961101
PT 801649	T	20021231	PT 1996-935195	19961101
RU 2206320	C2	20060620	RU 1997-113758	19961101
EE 4239	B1	20040216	EE 1997-146	19961101
CZ 295562	B6	20050817	CZ 1997-2072	19961101
SK 284823	B6	20051201	SK 1997-881	19961101
ZA 9609249	A	19980302	ZA 1996-9249	19961104
NO 9703059	A	19970902	NO 1997-3059	19970701
NO 321140	B1	20060327		
BG 63944	B1	20030731	BG 1997-101713	19970701
US 6653126	B1	20011125	US 1999-860582	19991207
US 2004019103	A1	20040129	US 2003-618157	20030710
US 7148239	B2	20061212		
US 2004067940	A1	20040408	US 2003-618162	20030710
PRIORITY APPLN. INFO.:			HU 1995-3141	A 19951102
			HU 1996-3919	A 19960209


L4 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 WO 1997-HU44 W 19970806

OTHER SOURCE(S): MARPAT 128:208909
 AB The invention relates to the use of certain hydroxylamine derivs. in the therapy or prevention of illnesses connected with the dysfunction of the vascular endothelial cells. Another object of the invention is the use of the same compds. in the preparation of pharmaceutical compns. against the above diseases. E.g.,
 N-[2-hydroxy-3-(1-piperidinyl)propoxyl]benzenecarboximidoyl chloride monohydrochloride was prepared and formulated into tablets.
 IT 203805-20-3P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (pharmaceuticals for curing and preventing illnesses connected with the malfunction of vascular endothelial cells)
 RN 203805-20-3 CAPLUS
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-(9CI) (CA INDEX NAME)




L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 HU 1996-29820 A 19961004
 WO 1996-HU64 W 19961101
 US 1999-860582 A3 19991207


OTHER SOURCE(S): MARPAT 127:55919
 AB A method of increasing expression of a mol. chaperon by a cell and/or enhancing the activity of a mol. chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiol. stress which induces expression of a mol. chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, a hydroxylamine derivative can be administered to a cell before it is exposed to a physiol. stress which induces expression of a mol. chaperon by the cell. Preferably, the cell to which a hydroxylamine derivative is administered is a eukaryotic cell. The invention also provides novel hydroxylamine derivs. falling within the scope of the formulas
 AZC(X)NOR (A = alkyl, substituted alkyl, aralkyl, substituted aralkyl, heteroaryl, etc.; Z = covalent bond, O, or NR3, where R3 = H, alkyl, substituted alkyl, aryl, etc.; R = alkyl or substituted alkyl; X = halo, substituted hydroxy or amino, substituted amino; R' = H, alkyl, substituted alkyl, aryl, substituted aryl, etc.) and AZC(X)N(R')OR (A = alkyl, substituted alkyl, aralkyl, substituted aralkyl, heteroaryl, etc.; Z = covalent bond, O, or NR3, where R3 = H, alkyl, substituted alkyl, aryl, etc.; R = alkyl or substituted alkyl; X = O, imino, or substituted imino; R' = H, alkyl, substituted alkyl, aryl, substituted aryl, etc.) as well as pharmaceutical and/or cosmetic compns. comprising the said compds.
 IT 203805-20-3P
 RL: PNU (Preparation, unclassified); PREP (Preparation)
 (hydroxylamine derivs. useful for enhancing mol. chaperon production and the preparation thereof)
 RN 203805-20-3 CAPLUS
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-(9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1987:470162 CAPLUS
 DOCUMENT NUMBER: 107:70162
 TITLE: Study of absorption of a new peripheral vasodilator compound (CH-141) by in vitro and in vivo methods. Part 2. Pharmacokinetic investigation of the compound
 AUTHOR(S): Szemere, L.; Mezei, J.; Kuttel, S.; Marton, S.; Racz, I.
 CORPORATE SOURCE: Gyógyszerészeti Intézet, Semmelweis Orvostud. Egy., Budapest, 1092, Hung.
 SOURCE: Acta Pharmaceutica Hungarica (1987), 57(1-2), 27-33
 CODEN: APHGAO; ISSN: 0001-6659
 DOCUMENT TYPE: Journal
 LANGUAGE: Hungarian
 GI




AB The pharmacokinetics of a new peripheral vasodilator compound, CH-141 (I), containing a 1,2,4-oxadiazine ring were discussed. Temporal formation of plasma levels of I was determined in rats following oral administration of I, and characteristic pharmacokinetic constants were given. The disappearance of I from strangulated rat stomach and rat bowels was followed. On the basis of these expts., the small intestine is the major site of I absorption, and absorption also occurs from the stomach in a smaller degree.
 IT 78279-88-6, CH 141
 RL: BIOL (Biological study)
 (pharmacokinetics and absorption of)
 RN 78279-88-6 CAPLUS
 CN Isoquinoline, 2-[(5,6-dihydro-3-phenyl-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1987:400519 CAPLUS
 DOCUMENT NUMBER: 107:519
 TITLE: Pharmacological investigations of the CH-141, a new isoquinolinoxadiazine derivative
 AUTHOR(S): Szegi, J.; Szentmiklosi, A. J.; Cséppento, Agnes; Szabo, J.; Takacs, E. I.; Nosztray, K.; Mezaros, J.; Takacs, K.
 CORPORATE SOURCE: Dep. Pharmacol., Univ. Med. Sch., Debrecen, Hung.
 SOURCE: Adv. Pharmacol. Res. Pract., Proc. Congr. Hung. Pharmacol. Soc., 4th (1986), Meeting Date 1985,
 Volume 1, 359-61. Editor(s): Knoll, Jozsef; Kelemen, Karoly.
 Pergamon: Oxford, UK.
 CODEN: SSNPA6
 CONFERENCE: English
 DOCUMENT TYPE: Conference
 LANGUAGE: English
 GI




AB CH 141 (I) lowered blood pressure in anesthetized cats and rabbits when administered i.v. (cats) and orally (rabbits). I also lowered blood pressure in exptl.-induced hypertensive cats when administered orally and had no effect on the heart rate. Peripheral circulation (perfused hind limb of cats) was increased by I. In Langendorff's heart preparation (rat) I (1-100 µg) had no effect on coronary flow or heart rate, but at 1 mg both parameters were decreased. I was found to be a strong α-adrenergic blocker. The i.v. LD50 of I in mice was 49.5 mg/kg.
 IT 78279-88-6, CH 141
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmacol. of, cardiovascular system in relation to)
 RN 78279-88-6 CAPLUS
 CN Isoquinoline, 2-[(5,6-dihydro-3-phenyl-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1985:509860 CAPLUS
 DOCUMENT NUMBER: 103:109860
 TITLE: Study of a new type peripheral vasodilator, the CH-141
 AUTHOR(S): Kovacs, Peter; Plachy, Janos; Szemere, Laszlo; Racz, Istvan
 CORPORATE SOURCE: Gyógyszerészeti Intézet, SOTE, Budapest, Hung.
 SOURCE: Acta Pharmaceutica Hungarica (1985), 55(3), 107-13
 CODEN: APHGAO; ISSN: 0001-6659
 DOCUMENT TYPE: Journal
 LANGUAGE: Hungarian
 AB The decomposition of CH-141 (78279-88-6) in aqueous solution followed 1st-order kinetics. The decomposition rate increased with the temperature (40-80°). CH-141 was stable at pH 4-7.
 IT 78279-88-6
 RL: PRP (Properties)
 (degradation of, in aqueous solution, kinetics of)
 RN 78279-88-6 CAPLUS
 CN Isoquinoline, 2-[(5,6-dihydro-3-phenyl-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1985:481229 CAPLUS
 DOCUMENT NUMBER: 103:61329
 TITLE: Absorption of a new peripheral vasodilator (CH-141), studied by in vitro and in vivo methods. I. In vitro modeling of the transport phenomena
 AUTHOR(S): Szemere, Laszlo; Marton, Sylvia
 CORPORATE SOURCE: CHINOMIN Gyogyszer Vegyszeti Termek Gyara, Budapest, Hung.
 SOURCE: Acta Pharmaceutica Hungarica (1985), 55(2), 59-67
 CODEN: APHGAO; ISSN: 0001-6659
 DOCUMENT TYPE: Journal
 LANGUAGE: Hungarian
 GI



AB The pK value of CH-141 (I) [78279-88-6], as determined by polarog., was 5. Partition coeffs. for I in water/heptane were determined at various pH values. No partition into the organic phase was observed at pH 5, whereas at pH >8, 90% of I was in the organic phase. Model studies on gastrointestinal absorption, indicated that little or no absorption of I could be expected in the stomach, but I should be significantly absorbed in the ileum.
 IT 78279-88-6
 RL: PROC (Process)
 (absorption of, in digestive tract)
 RN 78279-88-6 CAPLUS
 CN Isoquinoline, 2-[(5,6-dihydro-3-phenyl-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1985:411325 CAPLUS
 DOCUMENT NUMBER: 103:11325
 TITLE: Study of a new type of peripheric vasodilator, CH-141, in solution. Part 1. Analytical study of the compound, considering the selectivity of methods for stability testing
 AUTHOR(S): Kovacs, P.; Szemere, L.; Plachy, J.; Raczi, I.
 CORPORATE SOURCE: SOTE Gyogyszereszet Intez., Budapest, Hung.
 SOURCE: Acta Pharmaceutica Hungarica (1985), 55(1), 1-7
 CODEN: APHGAO; ISSN: 0001-6659
 DOCUMENT TYPE: Journal
 LANGUAGE: Hungarian
 AB TLC, HPLC, and potentiometric methods were developed for the thermal decomposition study of 3-phenyl-6-[(1,2,3,4-tetrahydro-2-isoquinoline)methyl-4H-5,6-dihydro-1,2,4-oxadiazine-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro-2-isoquinoline-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)
 IT 78267-97-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (thermal decomposition of, anal. methods for study of)
 RN 78267-97-7 CAPLUS
 CN Isoquinoline, 2-[(5,6-dihydro-3-phenyl-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1985:476134 CAPLUS
 DOCUMENT NUMBER: 103:76134
 TITLE: A new type of peripheric vasodilators, the CH-141 code-designated drug, in solution. Part 2. Mechanism of thermal decomposition and the identification of decomposition products
 AUTHOR(S): Kovacs, Peter; Plachy, Janos; Szemere, Laszlo; Raczi, Istvan
 CORPORATE SOURCE: SOTE Gyogyszereszet Int., Budapest, E. u. 7, Hung.
 SOURCE: Acta Pharmaceutica Hungarica (1985), 55(2), 85-91
 CODEN: APHGAO; ISSN: 0001-6659
 DOCUMENT TYPE: Journal
 LANGUAGE: Hungarian
 GI




AB The thermal degradation of CH-141 (I) [78279-88-6] in solution, at low pH, gave benzoic acid [65-85-0] and II [97612-08-3], as shown by TLC, UV spectrometry, HPLC, and potentiometry.
 IT 78279-88-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (thermal decomposition of)
 RN 78279-88-6 CAPLUS
 CN Isoquinoline, 2-[(5,6-dihydro-3-phenyl-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1985:125036 CAPLUS
 DOCUMENT NUMBER: 102:125036
 TITLE: Pharmacokinetic study of a new 1,2,4-oxadiazine derivative in rat
 AUTHOR(S): Mezei, Janos; Kuettel, Sandor; Raczi, Istvan
 CORPORATE SOURCE: Pharm. Inst., Semmelweis Med. Univ., Budapest, Hung.
 H-1092, Polish Journal of Pharmacology and Pharmacy (1984), 36(4), 397-400
 CODEN: PJPAAA; ISSN: 0301-0244
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB The pharmacokinetics of CH 141 (3-phenyl-6-[(1,2,3,4-tetrahydro-2-isoquinolyl)-methyl-4H-5,6-dihydro-1,2,4-oxadiazine(I)] (78279-88-6) in rat were studied. Plasma levels following a single oral dose were determined by a HPLC method. Basic plasma samples were partitioned with CHCl3. The organic layers were evaporated to dryness under reduced pressure. The residues were redissolved in CHCl3 and chromatographed on a microporous silica column with CHCl3-isopropanol (7:3) eluent. The pharmacokinetics of I obeyed the 1-compartment open model adequately. The plasma level vs. time curve was constructed and absorption and elimination rate consts. were calculated by linear regression
 anal. The rate of absorption proved to be significantly higher compared to that of elimination. The time of plasma level peak (tmax) was 35 min. After 20 h, only traces of I could be found in the plasma.
 IT 78279-88-6
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (pharmacokinetics of)
 RN 78279-88-6 CAPLUS
 CN Isoquinoline, 2-[(5,6-dihydro-3-phenyl-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1984:583330 CAPLUS
 DOCUMENT NUMBER: 101183320
 TITLE: High performance liquid chromatographic determination of a new biologically active 1,2,4-oxadiazine derivative in rat plasma
 AUTHOR(S): Mezei, J.; Kuettel, S.; Szemere, L.; Racz, I.
 CORPORATE SOURCE: Inst. Pharm., Semmelweis Univ. Med., Budapest, Hung.
 SOURCE: Pharmazie (1984), 39(6), 399-400
 CODEN: PHARAT; ISSN: 0031-7144
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




AB A sensitive HPLC procedure was developed for the determination of
 3-phenyl-6-(1,2,3,4-tetrahydro-2-isoquinolinyl)methyl-4H-5,6-dihydro-1,2,4-oxadiazine (I) [78279-88-6], a new vasodilator, in plasma. Rat plasma samples were made alkaline with ammonia and partitioned with CHCl₃. The extra. were dried and evaporated to dryness under reduced pressure. The residues were redissolved in CHCl₃, and then chromatographed on a silica column with CHCl₃/iso-PrOH (7:3). Detection was at 265 nm. The limit of identification was 10 ng, that of quant. determination 50 ng/mL plasma.
 The utility of the method for pharmacokinetic studies in the rat was demonstrated.
 IT 78279-88-6
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of, in blood by HPLC)
 RN 78279-88-6 CAPLUS
 CN Isoquinoline, 2-[(5,6-dihydro-3-phenyl-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1983:106658 CAPLUS
 DOCUMENT NUMBER: 98:106658
 TITLE: The MS investigation of 3,6-disubstituted-5,6-dihydro-4H-1,2,4-oxadiazine derivatives
 AUTHOR(S): Balla, J.; Mueller, T.; Brlik, J.; Erocsne-Takacsy, T.; Hollos, J.; Kissne-Ajvert, I.; Takacs, K.
 CORPORATE SOURCE: Inst. Gen. Anal. Chem., Tech. Univ., Budapest, H - 1111, Hung.
 SOURCE: International Journal of Mass Spectrometry and Ion Physics (1983), 47, 419-22
 CODEN: IJMSBY; ISSN: 0020-7381
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Mass-spectral fragmentation behavior of some new title oxadiazines I [R = Ph, CH₂C(OMe)₂, CH₂CHPh₂; R₁ = H, ClCH₂, HOCH₂, p-MeC₆H₄SO₂CH₂, piperidinomethyl, morpholinomethyl], of pharmacol. importance for circulation, were studied. Exact mass measurement, metastable-ion studies and D labeling showed that the complex ring fission is the most characteristic step of the fragmentation. It has 2 main possible pathways leading finally to the same result. The effect of the substituents on the main fragmentation processes is demonstrated.
 IT 56493-87-9 84868-05-3
 RL: PRP (Properties)
 (mass spectrum of)
 RN 56493-87-9 CAPLUS
 CN 4H-1,2,4-Oxadiazine, 5,6-dihydro-3-phenyl-6-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 84868-05-3 CAPLUS
 CN 2H-1,2,4-Oxadiazine, 5,6-dihydro-6-(4-morpholinylmethyl)-3-phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1981.443181 CAPLUS
 DOCUMENT NUMBER: 95:43181
 TITLE: 1,2,4-Oxadiazine derivatives and pharmaceutical compositions containing them
 PATENT ASSIGNEE(S): Chinoin Gyogyszer es Vegyeszeti Termek Gyara Rt., Hung.
 SOURCE: Belg., 28 pp.
 CODEN: BEXXAL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 885634	A1	19810202	BE 1980-202407	19801010
HU 21246	A2	19820830	HU 1979-CI1974	19791011
HU 180708	B	19810429		
IL 61176	A	19840531	IL 1980-61176	19800930
DE 3037747	A1	19810611	DE 1980-3037747	19801006
CS 249111	B2	19870312	CS 1980-6736	19801006
SE 8007026	A	19810412	SE 1980-7026	19801007
SE 448234	B	19870202		
SE 448234	C	19870514		
NL 8005587	A	19810414	NL 1980-5587	19801009
FR 2467204	A1	19810417	FR 1980-21625	19801009
FR 2467204	B1	19860328		
JP 56063970	A	19810530	JP 1980-140669	19801009
JP 02015547	B	19900412		
RO 81210	A1	19830201	RO 1980-102322	19801009
AT 8005012	A	19830515	AT 1980-5012	19801009
AT 373247	B	19831227		
RO 85269	A1	19840929	RO 1980-108150	19801009
DK 8004296	A	19810412	DK 1980-4296	19801010
DK 149106	B	19860127		
DK 149106	C	19860609		
FI 8003220	A	19810412	FI 1980-3220	19801010
FI 71932	B	19861128		
FI 71932	C	19870309		
NO 8003045	A	19810413	NO 1980-3045	19801010
NO 153652	B	19860120		
NO 153652	C	19860507		
GB 2062628	A	19810528	GB 1980-32827	19801010
GB 2062628	B	19830803		
ES 495820	A1	19810916	ES 1980-495820	19801010
US 4308270	A	19811229	US 1980-196034	19801010
DD 153551	A5	19820113	DD 1980-224477	19801010
CA 1159828	A1	19840103	CA 1980-362230	19801010
PL 129081	B1	19840331	PL 1980-227211	19801010
SU 1087520	A1	19840423	SU 1980-259202	19801010
PL 129378	B1	19840531	PL 1980-232264	19801010
CH 649540	A5	19850531	CH 1980-7600	19801010
AT 8302080	A	19840115	AT 1983-2080	19801067
AT 375658	B	19840827		
CS 249541	B2	19870312	CS 1985-1950	19850320

L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 PRIORITY APPLN. INFO.: HU 1979-CI1974 A 19791011
 CS 1980-6736 A3 19801006
 AT 1980-5012 A 19801009

OTHER SOURCE(S): MARPAT 95:43181
 G1




AB The 1,2,4-oxadiazines I [R = H, Ph, substituted phenyl; R1 = C1-4 alkyl, C5-7 cycloalkyl; R2 = C1-4 alkyl, acyl, H; R3 = H, C1-4 alkyl; R4 = C5-7 cycloalkyl, C1-6 alkyl, substituted phenyl; R3R4 = X (R5 = H, C1-4 alkyl), m, n = 0, 1, 2], useful as vasodilators and hypotensives, were prepared. Thus, the reaction of 3-phenyl-6-chloromethyl-5,6-dihydro-4H-1,2,4-oxadiazine and HNX (R5 = MeO) gave I [R = Ph, R1 = R2 = H, R3R4 = X (R5 = MeO)], which as its maleate had a hypotensive ED50 of 148 mg/kg i.v. in mice.
 IT 78267-94-4P 78267-97-7P 78268-00-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and antihypertensive activity of)
 RN 78267-94-4 CAPLUS
 CN 2H-1,2,4-Oxadiazine-6-methanamine, N-cyclohexyl-5,6-dihydro-3-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 78267-97-7 CAPLUS
 CN Isoquinoline, 2-[(5,6-dihydro-3-phenyl-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● 2 HCl

RN 78268-00-5 CAPLUS
 CN Isoquinoline, 2-[(5,6-dihydro-3-phenyl-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 78267-99-9
 CMF C21 H25 N3 O3



CM 2


CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.




IT 78267-95-5P 78267-99-9P 78268-02-7P
 78268-03-8P 78268-06-1P 78268-08-3P
 78268-15-2P 78268-16-3P 78279-88-6P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 78267-95-5 CAPLUS
 CN 2H-1,2,4-Oxadiazine-6-methanamine, N-cyclohexyl-5,6-dihydro-N-methyl-3-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● 2 HCl


RN 78267-99-9 CAPLUS
 CN Isoquinoline, 2-[(5,6-dihydro-3-phenyl-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-, (9CI) (CA INDEX NAME)



RN 78268-02-7 CAPLUS
 CN Isoquinoline, 2-[(3-(2-chlorophenyl)-5,6-dihydro-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro-, (9CI) (CA INDEX NAME)



RN 78268-03-8 CAPLUS
 CN Isoquinoline, 2-[(3-(2-chlorophenyl)-5,6-dihydro-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 78268-06-1 CAPLUS

03/27/2007


Habte

L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Isoquinoline, 2-[[5,6-dihydro-3-(4-methylphenyl)-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 78268-08-3 CAPLUS
 CN Isoquinoline, 2-[[5,6-dihydro-3-(phenylmethyl)-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 78268-15-2 CAPLUS
 CN Isoquinoline, 2-[[3-(4-chlorophenyl)-5,6-dihydro-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 78268-16-3 CAPLUS
 CN Isoquinoline, 2-[[3-(4-chlorophenyl)-5,6-dihydro-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro-, dihydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




● 2 HCl

RN 78279-88-6 CAPLUS
 CN Isoquinoline, 2-[[5,6-dihydro-3-phenyl-2H-1,2,4-oxadiazin-6-yl)methyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1975:479205 CAPLUS
 DOCUMENT NUMBER: 83:79205
 TITLE: 1,2,4-Oxadiazoles containing a C-5-heteroatom bond.
 II. Synthesis of 5,6-dihydro-4H-1,2,4-oxadiazines by ring extension of 3,4-dihydro-2H-1,2,4-oxadiazolin-5-ones
 Takacs, Kalman; Harsanyi, Kalman; Kolonits, Pal; Ajzert, K. Ilona
 Res. Lab., Chinoin Pharm. Chem. Works, Budapest, Hung.
 CORPORATE SOURCE: Chemische Berichte (1975), 108(6), 1911-23
 SOURCE: CODEN: CHBEAM; ISSN: 0009-2940
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 83:79205
 GI For diagram(s), see printed CA Issue.
 AB Oxadiazolinones I (R = Ph, Ph2CHCH2) reacted with alkylene oxides II (R1 = H, Me) or epichlorohydrin to give III (R = Ph, Ph2CHMe; R1 = H, Me, CH2Cl).
 The OH group of III (R1 = H, Me) was replaced with Cl and the product treated with alkali to give oxadiazines IV. III (R1 = H, Me) were used to prepare RC(:NOH)NHCH2CH(OH)R1, while RC(:NOH)NHCH2CH(OH)CH2R2 (R2 = piperidino, cyano) was obtained from III (R1 = CH2Cl). The reactivity of IV with MeI and acylating agents was discussed.
 IT 56493-87-9P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 56493-87-9 CAPLUS
 CN 4H-1,2,4-Oxadiazine, 5,6-dihydro-3-phenyl-6-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)



K1
Day : Tuesday
Date: 3/27/2007

Time: 14:45:23

 **PALM INTRANET**

Inventor Information for 10/501029

Inventor Name	City	State/Country
<u>CSAKAI, ZITA JEGESNE</u>	VILONYA	HUNGARY
<u>MARVANYOS, EDE</u>	BUDAPEST	HUNGARY
<u>UROGDI, LASZLO</u>	BUDAPEST	HUNGARY
<u>TOROK, MAGDOLNA BATHONE</u>	BALATONFURED	HUNGARY
<u>DENES, LASZLO</u>	BUDAPEST	HUNGARY

[Appln Info](#)[Contents](#)[Petition Info](#)[Atty/Agent Info](#)[Continuity/Reexam](#)[Foreign I](#)

Search Another: Application#

or Patent#

PCT /

 /

or PG PUBS #

Attorney Docket #

Bar Code #

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	142	544/66.ccls.	USPAT	OR	OFF	2007/03/27 14:39
L2	183	514/222.5.ccls.	USPAT	OR	OFF	2007/03/27 14:39
L3	311	I1 I2	USPAT	OR	OFF	2007/03/27 14:37
L4	18	544/66.ccls.	US-PGPUB	OR	OFF	2007/03/27 14:39
L5	52	514/222.5.ccls.	US-PGPUB	OR	OFF	2007/03/27 14:39
L6	69	I4 I5	US-PGPUB	OR	OFF	2007/03/27 14:39